Promising molecular mechanisms responsible for gemcitabine resistance in cancer

Yanfei Jia, Jingwu Xie

Research output: Contribution to journalReview article

22 Citations (Scopus)

Abstract

Gemcitabine is the first-line treatment for pancreatic ductual adenocarcinoma (PDAC) as well as acts against a wide range of other solid tumors. Patients usually have a good initial response to gemcitabine-based chemotherapy but would eventually develop resistance. To improve survival and prognosis of cancer patients, better understanding of the mechanisms responsible for gemcitabine resistance and discovery of new therapeutic strategies are in great need. Amounting evidence indicate that the developmental pathways, such as Hedgehog (Hh), Wnt and Notch, become reactivated in gemcitabine-resistant cancer cells. Thus, the strategies for targeting these pathways may sensitize cancer cells to gemcitabine treatment. In this review, we will summarize recent development in this area of research and discuss strategies to overcome gemcitabine resistance. Given the cross-talk between these three developmental signaling pathways, designing clinical trials using a cocktail of inhibitory agents targeting all these pathways may be more effective. Ultimately, our hope is that targeting these developmental pathways may be an effective way to improve the gemcitabine treatment outcome in cancer patients.

Original languageEnglish (US)
Pages (from-to)299-306
Number of pages8
JournalGenes and Diseases
Volume2
Issue number4
DOIs
StatePublished - Dec 1 2015

Fingerprint

gemcitabine
Neoplasms
Cells
Chemotherapy
Tumors
Adenocarcinoma
Therapeutics
Clinical Trials

Keywords

  • Cancer therapy
  • Gemcitabine resistance
  • Hedgehog
  • Notch
  • Wnt

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology
  • Genetics(clinical)

Cite this

Promising molecular mechanisms responsible for gemcitabine resistance in cancer. / Jia, Yanfei; Xie, Jingwu.

In: Genes and Diseases, Vol. 2, No. 4, 01.12.2015, p. 299-306.

Research output: Contribution to journalReview article

@article{16546d6d22d144fea4d3568b37b41d4f,
title = "Promising molecular mechanisms responsible for gemcitabine resistance in cancer",
abstract = "Gemcitabine is the first-line treatment for pancreatic ductual adenocarcinoma (PDAC) as well as acts against a wide range of other solid tumors. Patients usually have a good initial response to gemcitabine-based chemotherapy but would eventually develop resistance. To improve survival and prognosis of cancer patients, better understanding of the mechanisms responsible for gemcitabine resistance and discovery of new therapeutic strategies are in great need. Amounting evidence indicate that the developmental pathways, such as Hedgehog (Hh), Wnt and Notch, become reactivated in gemcitabine-resistant cancer cells. Thus, the strategies for targeting these pathways may sensitize cancer cells to gemcitabine treatment. In this review, we will summarize recent development in this area of research and discuss strategies to overcome gemcitabine resistance. Given the cross-talk between these three developmental signaling pathways, designing clinical trials using a cocktail of inhibitory agents targeting all these pathways may be more effective. Ultimately, our hope is that targeting these developmental pathways may be an effective way to improve the gemcitabine treatment outcome in cancer patients.",
keywords = "Cancer therapy, Gemcitabine resistance, Hedgehog, Notch, Wnt",
author = "Yanfei Jia and Jingwu Xie",
year = "2015",
month = "12",
day = "1",
doi = "10.1016/j.gendis.2015.07.003",
language = "English (US)",
volume = "2",
pages = "299--306",
journal = "Genes and Diseases",
issn = "2352-3042",
publisher = "Elsevier BV",
number = "4",

}

TY - JOUR

T1 - Promising molecular mechanisms responsible for gemcitabine resistance in cancer

AU - Jia, Yanfei

AU - Xie, Jingwu

PY - 2015/12/1

Y1 - 2015/12/1

N2 - Gemcitabine is the first-line treatment for pancreatic ductual adenocarcinoma (PDAC) as well as acts against a wide range of other solid tumors. Patients usually have a good initial response to gemcitabine-based chemotherapy but would eventually develop resistance. To improve survival and prognosis of cancer patients, better understanding of the mechanisms responsible for gemcitabine resistance and discovery of new therapeutic strategies are in great need. Amounting evidence indicate that the developmental pathways, such as Hedgehog (Hh), Wnt and Notch, become reactivated in gemcitabine-resistant cancer cells. Thus, the strategies for targeting these pathways may sensitize cancer cells to gemcitabine treatment. In this review, we will summarize recent development in this area of research and discuss strategies to overcome gemcitabine resistance. Given the cross-talk between these three developmental signaling pathways, designing clinical trials using a cocktail of inhibitory agents targeting all these pathways may be more effective. Ultimately, our hope is that targeting these developmental pathways may be an effective way to improve the gemcitabine treatment outcome in cancer patients.

AB - Gemcitabine is the first-line treatment for pancreatic ductual adenocarcinoma (PDAC) as well as acts against a wide range of other solid tumors. Patients usually have a good initial response to gemcitabine-based chemotherapy but would eventually develop resistance. To improve survival and prognosis of cancer patients, better understanding of the mechanisms responsible for gemcitabine resistance and discovery of new therapeutic strategies are in great need. Amounting evidence indicate that the developmental pathways, such as Hedgehog (Hh), Wnt and Notch, become reactivated in gemcitabine-resistant cancer cells. Thus, the strategies for targeting these pathways may sensitize cancer cells to gemcitabine treatment. In this review, we will summarize recent development in this area of research and discuss strategies to overcome gemcitabine resistance. Given the cross-talk between these three developmental signaling pathways, designing clinical trials using a cocktail of inhibitory agents targeting all these pathways may be more effective. Ultimately, our hope is that targeting these developmental pathways may be an effective way to improve the gemcitabine treatment outcome in cancer patients.

KW - Cancer therapy

KW - Gemcitabine resistance

KW - Hedgehog

KW - Notch

KW - Wnt

UR - http://www.scopus.com/inward/record.url?scp=84978081268&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84978081268&partnerID=8YFLogxK

U2 - 10.1016/j.gendis.2015.07.003

DO - 10.1016/j.gendis.2015.07.003

M3 - Review article

C2 - 30258872

AN - SCOPUS:84978081268

VL - 2

SP - 299

EP - 306

JO - Genes and Diseases

JF - Genes and Diseases

SN - 2352-3042

IS - 4

ER -